In this current study we demonstrate that niclosamide not only targets the Wnt pathway, but it also targets the mTOR and the STAT3 pathways and specifically targets CD133+ CSCs and chemoresistant cells isolated from a PDX ovarian cancer model. The gene discussed is PROM1; the disease is ovarian cancer.